Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $10.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on SGMO. Jefferies Financial Group lowered their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday. Truist Financial upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Friday, December 13th. Barclays upped their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Wells Fargo & Company decreased their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday. Finally, StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $1.13 on Thursday. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18. The firm has a market cap of $235.77 million, a price-to-earnings ratio of -1.51 and a beta of 1.15. The business’s fifty day moving average is $2.14 and its 200-day moving average is $1.22.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $49.41 million for the quarter, compared to the consensus estimate of $26.55 million. During the same quarter last year, the business posted ($0.34) EPS. As a group, research analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors have recently modified their holdings of the business. Meritage Portfolio Management increased its holdings in Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 64,981 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 38,850 shares during the period. Virtu Financial LLC purchased a new position in Sangamo Therapeutics during the 3rd quarter valued at about $150,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics during the second quarter valued at about $67,000. 56.93% of the stock is owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.